Basics Sarepta Therapeutics, Inc. Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases. IPO Date: July 12, 2012 Sector: Healthcare Industry: Biotech Market Cap: $2.33B Activated in VL: True Average Daily Range Avg Daily Range: $1.53 | 2.46% Avg Daily Range (30 D): $0.75 | 3.98% Avg Daily Range (90 D): $0.63 | 3.31% Institutional Daily Volume Avg Daily Volume: 1.81M Avg Daily Volume (30 D): 4.56M Avg Daily Volume (90 D): 6.39M Trade Size Avg Trade Size (Sh.): 107 Avg Trade Size (Sh.) (30 D): 85 Avg Trade Size (Sh.) (90 D): 109 Institutional Trades Total Inst.Trades: 13,671 Avg Inst. Trade: $4.05M Avg Inst. Trade (30 D): $3.8M Avg Inst. Trade (90 D): $3.6M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $8.79M Avg Closing Trade (30 D): $9.21M Avg Closing Trade (90 D): $11.55M Avg Closing Volume: 119.68K     News Nov 4, 2025 @ 5:11 PM Sarepta Stock Dumps: Pharma Bro Martin Shkreli Sti... Source: Erica Kollmann Oct 7, 2025 @ 3:00 PM AAV Gene Therapy Market Size to Skyrocket at 40.1%... Source: Towards Healthcare Sep 5, 2025 @ 1:30 PM 2 Beaten-Down Stocks to Avoid Right Now Source: Prosper Junior Bakiny Aug 29, 2025 @ 7:13 PM SRPT Stock Alert: Investors with Large Losses Shou... Source: Robbins Llp Aug 28, 2025 @ 3:00 PM Genetic Material Market Size, Trends and Top Compa... Source: Towards Healthcare Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.8 $2.01 $-4.6 Diluted EPS $-1.8 $1.89 $-4.6 Revenue $ 399.36M $ 611.09M $ 744.86M Gross Profit $ $ $ Net Income / Loss $ -179.95M $ 196.89M $ -447.51M Operating Income / Loss $ -103.39M $ 115.58M $ -300.39M Cost of Revenue $ $ $ Net Cash Flow $ 100.03M $ 269.73M $ -862.14M PE Ratio     Splits Jul 12, 2012:   1:6